Molecular and prognosis characteristics of NFE2-mutated MPN patients. (A) Flowchart of the study and proportion of patients with sequential NGS analysis. (B) NFE2 mutations positioned on the NFE2 protein sequence with its main functional domains. The y-axis represents the frequency of each mutation. (C) Time of detection of NFE2 mutations during MPN clinical course. (D) Circos plot depicting mutational associations in NFE2-mutated patients and their relative frequency. (E) acute myeloid leukemia / myelodysplastic syndrome (AML/MDS) TFS of NFE2-mutated compared with non–NFE2-mutated MPN patients. (F) AML/MDS TFS of NFE2-mutated MPN patients. (G) Overall Survival (OS) of NFE2-mutated compared with non–NFE2-mutated MPN patients. For OS and Transformation Free Survival (TFS) representation, all patients started in the non–NFE2-mutated group and populated the NFE2-mutated group after NFE2 mutation identification. These analyses only included the 707 MPN patients in whom NFE2 mutational status was available.